DiaMedica Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . DiaMedica Therapeutics
DMAC Stock  USD 4.18  0.25  6.36%   
DiaMedica Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing DiaMedica Therapeutics' valuation are provided below:
Market Capitalization
179.3 M
Earnings Share
(0.64)
We have found one hundred twenty available fundamental signals for DiaMedica Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of DiaMedica Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 207.3 M. The current year's Enterprise Value is expected to grow to about 204.8 M

DiaMedica Therapeutics Total Revenue

500,000

Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 25.6 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 5.12. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with DiaMedica Stock
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

DiaMedica Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets48.7 M46.3 M18.9 M
Slightly volatile
Short and Long Term Debt Total285.8 K340 K344 K
Slightly volatile
Other Current Liabilities4.7 M4.5 M1.2 M
Slightly volatile
Total Current Liabilities5.7 M5.4 M2 M
Slightly volatile
Property Plant And Equipment Net448.4 K427 K166.2 K
Slightly volatile
Accounts Payable580 K940 K634.9 K
Pretty Stable
Cash3.5 M3 M3.7 M
Slightly volatile
Non Current Assets Total1.8 M1.7 M705 K
Very volatile
Cash And Short Term Investments46.4 M44.1 M17.8 M
Slightly volatile
Net Receivables183.2 K236 K199.9 K
Slightly volatile
Common Stock Shares Outstanding42.4 M40.4 M13.9 M
Slightly volatile
Liabilities And Stockholders Equity48.7 M46.3 M18.9 M
Slightly volatile
Other Stockholder Equity189.7 M180.7 M70 M
Slightly volatile
Total Liabilities5.9 M5.6 M2.1 M
Slightly volatile
Property Plant And Equipment Gross568 K541 K191.2 K
Slightly volatile
Total Current Assets46.8 M44.6 M18.2 M
Slightly volatile
Property Plant Equipment676.2 K644 K191.8 K
Slightly volatile
Capital Surpluse114.6 M109.2 M50 M
Slightly volatile
Net Invested Capital30.1 M40.7 M15.9 M
Slightly volatile
Net Working Capital29.7 M39.2 M15.6 M
Slightly volatile

DiaMedica Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization25.6 K27 K374 K
Slightly volatile
Other Operating Expenses25.7 M24.5 M10.4 M
Slightly volatile
Research Development20 M19.1 M6.9 M
Slightly volatile
Total Operating Expenses28 M26.7 M10.7 M
Slightly volatile
Selling General Administrative8 M7.6 M3.6 M
Slightly volatile
Interest Income47.1 K44.9 K21.7 K
Slightly volatile
Reconciled Depreciation24.3 K39 K14.3 K
Slightly volatile
Selling And Marketing Expenses24 K27 K29.4 K
Slightly volatile

DiaMedica Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.3 M4.5 M3.7 M
Slightly volatile
Depreciation37 K39 K375.5 K
Slightly volatile
Capital Expenditures23.8 K25 K45 K
Slightly volatile
End Period Cash Flow3.5 M3 M3.7 M
Slightly volatile
Stock Based Compensation2.2 M2.1 M1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio49.2451.8363.5584
Slightly volatile
Days Sales Outstanding358512531
Very volatile
Invested Capital2.5 M2.6 M2.9 M
Slightly volatile
Average Payables600.3 K571.7 K558.4 K
Slightly volatile
Stock Based Compensation To Revenue0.991.121.2169
Slightly volatile
Capex To Depreciation0.610.6413.1775
Slightly volatile
EV To Sales12.5313.1931.8452
Slightly volatile
Inventory Turnover0.230.241.3 K
Slightly volatile
Days Of Inventory On Hand1.6 K1.5 K914
Slightly volatile
Payables Turnover0.02710.02920.0298
Slightly volatile
Sales General And Administrative To Revenue4.384.935.3751
Slightly volatile
Research And Ddevelopement To Revenue11.9210.49.5955
Very volatile
Capex To Revenue0.110.120.2865
Slightly volatile
Cash Per Share0.961.09260.968
Slightly volatile
Days Payables Outstanding12.3 K13 K31.2 K
Slightly volatile
Income Quality1.050.90310.8264
Slightly volatile
Intangibles To Total Assets0.10.110.1835
Slightly volatile
Current Ratio6.448.27648.0833
Slightly volatile
Receivables Turnover1.170.740.7462
Pretty Stable
Capex Per Share6.0E-46.0E-40.0327
Slightly volatile
Average Receivables51.7 K29 K30.3 K
Pretty Stable
Revenue Per Share0.07680.05810.0687
Slightly volatile
Interest Debt Per Share0.0080.00840.0796
Slightly volatile
Debt To Assets0.0070.00730.9714
Slightly volatile
Operating Cycle1.6 K1.5 K747
Slightly volatile
Days Of Payables Outstanding12.3 K13 K31.2 K
Slightly volatile
Ebt Per Ebit1.080.9150.9639
Very volatile
Quick Ratio6.438.27648.0736
Slightly volatile
Net Income Per E B T1.121.00121.0211
Very volatile
Cash Ratio0.530.56122.6482
Very volatile
Days Of Inventory Outstanding1.6 K1.5 K914
Slightly volatile
Days Of Sales Outstanding358512531
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.191.00111.0835
Slightly volatile
Fixed Asset Turnover4.924.694.9407
Slightly volatile
Debt Ratio0.0070.00730.9714
Slightly volatile
Price Sales Ratio49.2451.8363.5584
Slightly volatile
Asset Turnover0.02980.03140.0358
Slightly volatile

DiaMedica Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap207.3 M197.5 M77.9 M
Slightly volatile
Enterprise Value204.8 M195 M74.3 M
Slightly volatile

DiaMedica Fundamental Market Drivers

Cash And Short Term Investments44.1 M

DiaMedica Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About DiaMedica Therapeutics Financial Statements

DiaMedica Therapeutics stakeholders use historical fundamental indicators, such as DiaMedica Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DiaMedica Therapeutics' assets and liabilities are reflected in the revenues and expenses on DiaMedica Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue30.6 K32.1 K
Cost Of Revenue34.5 K36.2 K
Stock Based Compensation To Revenue 1.12  0.99 
Sales General And Administrative To Revenue 4.93  4.38 
Research And Ddevelopement To Revenue 10.40  11.92 
Capex To Revenue 0.12  0.11 
Revenue Per Share 0.06  0.08 
Ebit Per Revenue(12.17)(12.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GOOGAlphabet Inc Class C
VVisa Class A
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
How To Invest In DiaMedica
Details
Is DiaMedica Stock a good investment?
Details
What is DiaMedica Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.64)
Return On Assets
(0.41)
Return On Equity
(0.67)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY